Spots Global Cancer Trial Database for Transabdominal Ultrasound With BR55 for Characterization of Pancreatic Lesions
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Transabdominal Ultrasound With BR55 for Characterization of Pancreatic Lesions
Official Title: Transabdominal Ultrasound With BR55 for Characterization of Pancreatic Lesions
Study ID: NCT03486327
Conditions
Interventions
Study Description
Brief Summary: This is an exploratory, single center, open label, parallel-dose, and prospective study of BR55 CEUS for characterization of solid pancreatic lesions in subjects with suspected PDAC using transabdominal US.
Detailed Description: Approximately twenty-four (24) subjects with suspected PDAC and scheduled to undergo surgical resection within 30 days (but not before 24 hours) after the transabdominal BR55 CEUS examination will be enrolled into 3 dose groups, 0.03, 0.05, and 0.08 mL/kg, with a maximum of 8 patients in each dose group.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Stanford University Medical Center, Palo Alto, California, United States
Contact Details
Name: Maria Luigia Storto, MD
Affiliation: Bracco Diagnostics, Inc
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
